TY - JOUR
T1 - Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer
AU - Aoki, Yoichi
AU - Ochiai, Kazunori
AU - Lim, Soyi
AU - Aoki, Daisuke
AU - Kamiura, Shoji
AU - Lin, Hao
AU - Katsumata, Noriyuki
AU - Cha, Soon Do
AU - Kim, Jae Hoon
AU - Kim, Byoung Gie
AU - Hirashima, Yasuyuki
AU - Fujiwara, Keiichi
AU - Kim, Young Tak
AU - Kim, Seok Mo
AU - Chung, Hyun Hoon
AU - Chang, Ting Chang
AU - Kamura, Toshiharu
AU - Takizawa, Ken
AU - Takeuchi, Masahiro
AU - Kang, Soon Beom
N1 - Funding Information:
We thank all the patients, their families, and the investigators who participated in this study. We thank all the members of the independent data monitoring committee: Yutaka Ariyoshi (Aichi Cancer Center Aichi Hospital), Hiroyuki Yoshikawa (Ibaraki Prefectural Central Hospital), and Junzo Kigawa (Matsue City Hospital) for their contribution, and Kentaro Tsuji (Taiho Pharmaceutical Co., Ltd.) for his support in compiling and writing this report. This study was collaborated with the Japanese Gynecologic Oncology Group. Medical writing assistance was provided by Chiaki Fukuhara, Ph.D., and ASCA Corp, and funded by Taiho Pharmaceutical Co., Ltd. There is no applicable grant number.
Publisher Copyright:
© 2018, The Author(s).
PY - 2018/8/28
Y1 - 2018/8/28
N2 - Background: This open-label phase III trial evaluated efficacy and safety of S-1 plus cisplatin vs. cisplatin alone as first-line chemotherapy in patients with stage IVB, recurrent, or persistent cervical cancer. Methods: Patients were randomised (1:1) to S-1 plus cisplatin (study group) or cisplatin alone (control group). In each cycle, cisplatin 50 mg/m2 was administered on Day 1 in both groups. S-1 was administered orally at 80–120 mg daily on Days 1–14 of a 21-day cycle in the study group. The primary endpoint was overall survival (OS). Results: A total of 375 patients were enrolled, of whom 364 (188, study group; 176, control group) received treatment. Median OS was 21.9 and 19.5 months in the study and control groups, respectively (log-rank P = 0.125; hazard ratio [HR] 0.84, 95% confidence interval [CI] 0.67–1.05). Median progression-free survival (PFS) was 7.3 and 4.9 months in the study and control groups, respectively (HR 0.62, 95% CI 0.48–0.80, P < 0.001). The adverse event (AE) rate increased in the study group despite the absence of any unexpected AEs. Conclusions: S-1 plus cisplatin did not show superiority over cisplatin alone in OS but significantly increased PFS in patients with stage IVB, recurrent, or persistent cervical cancer. Since the standard therapy has changed in the course of this study, further studies are warranted to confirm the clinical positioning of S-1 combined with cisplatin for this population.
AB - Background: This open-label phase III trial evaluated efficacy and safety of S-1 plus cisplatin vs. cisplatin alone as first-line chemotherapy in patients with stage IVB, recurrent, or persistent cervical cancer. Methods: Patients were randomised (1:1) to S-1 plus cisplatin (study group) or cisplatin alone (control group). In each cycle, cisplatin 50 mg/m2 was administered on Day 1 in both groups. S-1 was administered orally at 80–120 mg daily on Days 1–14 of a 21-day cycle in the study group. The primary endpoint was overall survival (OS). Results: A total of 375 patients were enrolled, of whom 364 (188, study group; 176, control group) received treatment. Median OS was 21.9 and 19.5 months in the study and control groups, respectively (log-rank P = 0.125; hazard ratio [HR] 0.84, 95% confidence interval [CI] 0.67–1.05). Median progression-free survival (PFS) was 7.3 and 4.9 months in the study and control groups, respectively (HR 0.62, 95% CI 0.48–0.80, P < 0.001). The adverse event (AE) rate increased in the study group despite the absence of any unexpected AEs. Conclusions: S-1 plus cisplatin did not show superiority over cisplatin alone in OS but significantly increased PFS in patients with stage IVB, recurrent, or persistent cervical cancer. Since the standard therapy has changed in the course of this study, further studies are warranted to confirm the clinical positioning of S-1 combined with cisplatin for this population.
UR - http://www.scopus.com/inward/record.url?scp=85052911054&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052911054&partnerID=8YFLogxK
U2 - 10.1038/s41416-018-0206-7
DO - 10.1038/s41416-018-0206-7
M3 - Article
C2 - 30072745
AN - SCOPUS:85052911054
SN - 0007-0920
VL - 119
SP - 530
EP - 537
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 5
ER -
